Patients with restrictive cardiomyopathy (RCM) and hypertrophic cardiomyopathy (HCM) generally are considered poor candidates for mechanical circulatory support devices (MCSDs) and often not able to be bridged mechanically to heart transplantation. This study characterized MCSD utilization and transplant waitlist outcomes in patients with RCM/HCM under the current allocation system and discusses changes in the era of the new donor allocation system.
O
ver the past decade, mechanical circulatory support device (MCSD) therapy has revolutionized care of patients with acute and chronic endstage heart failure, irrespective of transplant eligibility. [1] [2] [3] [4] [5] MCSDs-particularly durable left ventricular assist devices (LVADs)-have been preferentially used in patients with dilated cardiomyopathy (DCM). 1, 6, 7 Cardiomyopathies with a primary restrictive physiology-including cardiac amyloidosis, restrictive cardiomyopathy (RCM), and hypertrophic cardiomyopathy (HCM)-are complex and have distinct pathophysiological mechanisms. RCM is characterized by abnormalities in ventricular filling and compliance that lead to elevated intracardiac pressures and distortion of atrial and ventricular myocardium. HCM shares similar changes in hemodynamics but is more clinically heterogeneous and driven primarily by hypertrophy of the ventricular myocardium. 8, 9 As a result, patients with RCM/HCM have a clinical course that is distinct from those with DCM, even at advanced stages. Smaller ventricular size, increased myocardial stiffness, and reduced ventricular capacitance observed in these patients may result in cannula obstruction, suction events, inadequate pump flows, and pump thrombosis. 10, 11 As such, MCSD use is generally deferred in HCM/RCM population because of structural impediments in the context of their distinctive physiology.
In December 2016, the Thoracic Organ Transplantation Committee of the Organ Procurement and Transplantation Network/United Network for Organ Sharing (UNOS) approved a new heart allocation policy for the United States. 12, 13 It used a thoracic simulation allocation model, performed by the Scientific Registry of Transplant Recipients, to determine status hierarchy. Based on this modeling, patients with temporary and durable MCSD will be prioritized in statuses 1/2/3 under the new policy (Table 1) . [12] [13] [14] [15] As a result, patients for whom MCSD is not an appropriate physiological option-such as patients with RCM/HCM-may be disadvantaged. In the new allocation system, these patients will be categorized as status 4 (and only if they meet specific listing criteria, such as cardiac index ≤1.8 L/min per m 2 and pulmonary capillary wedge pressure [PCWP] >20 mm Hg).
This shift in the United States' organ recipient prioritization of MCSD patients coupled with the unique challenges of RCM/HCM management brings to light questions of current MCSD use and heart transplant waitlist outcomes for patients with RCM/HCM. Answers to these questions can help identify vulnerable patients with RCM/HCM under the new allocation policy and provide effective guidance for transplant centers. Primary objectives of this study were (1) to investigate MCSD utilization patterns, waitlist time, incidence of waitlist death, and incidence of heart transplantation
WHAT IS NEW?
• This study quantifies the probability of mechanical circulatory support device utilization, waitlist outcomes, and predictors of clinical deterioration for patients with restrictive cardiomyopathy/hypertrophic cardiomyopathy (RCM/HCM). Under the current allocation system, patients with RCM/HCM have decreased mechanical circulatory support device utilization, shorter waitlist times, increased incidence of transplantation, and equivalent waitlist mortality as other patients. • Significant predictors of clinical deterioration or death for patients with RCM/HCM are frailty, estimated glomerular filtration rate <60 mL/min per 1.73 m 2 , mean pulmonary capillary wedge pressure >20 mm Hg, and inotrope use at listing.
WHAT ARE THE CLINICAL IMPLICATIONS?
• This study provides clinicians a practical tool with which to risk stratify patients with RCM/HCM. The United Network for Organ Sharing RCM/HCM risk model can be applied at the bedside.
• The United Network for Organ Sharing RCM/HCM risk model can be helpful in 2 ways: to assess any given RCM/HCM patient's risk for adverse events (death or clinical deterioration) and to identify which patients with RCM/HCM on the heart transplantation waitlist may benefit most from status exceptions under the new allocation system. These patients should be considered for expedited transplant. BiVAD indicates biventricular assist device; HCM, hypertrophic cardiomyopathy; IABP, intra-aortic balloon pump; LVAD, left ventricular assist device; MCSD, mechanical circulatory support devices; PCWP, pulmonary capillary wedge pressure; RCM, restrictive cardiomyopathy; TAH, total artificial heart; VA-ECMO, veno-arterial extracorporeal membrane oxygenation; VAD, ventricular assist device; and VT/VF, ventricular tachycardia/ventricular fibrillation.
*Dischargeable MCS includes total artificial heart, a right VAD, or a BiVAD. †Complications may include pump thrombosis, right heart failure, bleeding, aortic insufficiency, device infection, and hemolysis.
in patients with RCM/HCM; (2) to derive a UNOS RCM/ HCM risk model for patients with RCM/HCM without MCSD to identify those at higher risk for clinical deterioration on the heart transplant waitlist as a strategy to safeguard their outcomes and validate their prioritization as status exceptions on the waitlist.
METHODS

Data Source and Clinical Variables
Deidentified patient-level data were obtained from the UNOS Thoracic Registry. Waitlist candidates for first heart transplantation were stratified into 2 cohorts: patients with RCM/ HCM versus those with other diagnoses (such as DCM and ischemic cardiomyopathy). Devices included in the analyses were veno-arterial extracorporeal membrane oxygenation, intra-aortic balloon pump, LVAD, and right ventricular assist device. For contemporaneous MCSD assessment focusing on continuous-flow technology, we used only data from 2006 through March 2016.
Baseline clinical characteristics studied included age at listing, sex, ethnicity, pathogenesis of heart failure, renal function, body mass index, and UNOS status at listing. In this study, the frailty measure used was imputed from clinicians' subjective assessment on the UNOS questionnaire at the time of listing. The UNOS questionnaire allows clinicians to rank patients in deciles according to the level and frequency of medical assistance required, their ability to perform activities of daily living, and their ability to carry-on their normal work. In this study, patients ranked in the most severe 5 strata of this scale-ranging from moribund to requires considerable assistance and frequent medical care-were classified as frail. The study was submitted to the Institutional Review Board of Columbia University Medical Center and was determined to be exempt from review.
Statistical Methods
To determine the probability of MCSD utilization and waitlist time, unadjusted, univariate numbers were first determined. These values were cross-checked by sensitivity analyses done by propensity score-matched (PSM) models that included progressively more covariates. Initial PSM models controlling for sex, age, and UNOS region were created to compare RCM/HCM versus non-RCM/HCM cohorts for all patients and separately for those in status 1A at the time of listing. Follow-up PSM models for all patients controlled for sex, age, UNOS region, ethnicity, body mass index, and blood type O status. The incidence of waitlist mortality and transplant for RCM/HCM versus non-RCM/HCM patients were modeled by cumulative incidence functions (CIFs) with competing events. Each CIF was modeled as the subdistribution hazard of the event of interest against the competing risks faced by every patient while on the waitlist: mortality, heart transplantation, and waitlist removal for other reasons. All CIFs controlled for age, sex, UNOS region, ethnicity, body mass index, and blood type O status.
Predictors of clinical deterioration while on the waitlist for patients with RCM/HCM without MCSD support were identified to create a validated risk model. Clinical deterioration was defined as waitlist death or delisting for worsening clinical status. Risk modeling was done in 4 steps. First, derivation and validation cohorts were created from random sampling of the overall RCM/HCM population in the UNOS registry. Two thirds of the patients were randomized to the derivation cohort, and the remaining one third were randomized to the validation cohort. Second, relevant clinical variables were identified with the goal of optimizing the prediction of the composite outcome of waitlist death or delisting in the RCM/HCM derivation cohort. Hemodynamic data, key laboratory data, comorbidities, and frailty were assessed in univariate Cox proportional hazards models. An optimal threshold for PCWP was defined by deriving time-dependent receiver operating characteristic (ROC) curves for the univariate prediction of clinical deterioration and choosing the cutoff that maximized Youden index (defined as sensitivity+specificity-1). Third, significant univariate predictors were included in a multivariate proportional hazards model. In the final UNOS RCM/ HCM risk model proposed here, predictors were weighted equally for simplicity of clinical use, particularly given the limited variation in the predictors' relative adjusted hazard contribution. Fourth, the UNOS RCM/HCM risk model was tested on the validation cohort. Time-dependent ROC curves were created to determine its test characteristics using each possible cutoff value with overall test performance evaluated using the area under the curve. ROC curves were created for the entire cohort and separately for patients with RCM versus patients with HCM. Kaplan-Meier curves based on UNOS RCM/HCM risk score were derived for the entire cohort. End points were waitlist death or delisting for clinical deteroriation, and curves were censored for transplantation. A P<0.05 was considered significant. Analyses were performed using Stata/IC version 14 software (StataCorp, College Station, TX).
RESULTS
Baseline Characteristics
There were 1562 patients in the RCM/HCM cohort and 29 046 patients in the non-RCM/HCM cohort ( (Table I in 
Waitlist Duration in Patients With RCM/ HCM
On univariate analysis, the mean days on the waitlist for patients with RCM/HCM was lower than for the non-RCM/HCM cohort (262.5 versus 293.6 days; P<0.01; Table 2 ). After PSM, the average treatment effect of an RCM/HCM diagnosis was 37.0 to 46.2 days fewer on the transplant waitlist (P<0.01; Figure III in the Data Supplement). Among only patients in status 1A at the time of listing, the PSM model showed that an average treatment effect of an RCM/HCM diagnosis was 56.2 days fewer on the transplant waitlist (P<0.01; Figure IV in the Data Supplement).
Transplant Waitlist Outcomes in Patients With RCM/HCM
The 3 competing risks faced by patients on the waitlist (waitlist death, heart transplantation, and waitlist removal for other reasons) were modeled to determine the incidence of waitlist death and transplant for the 2 cohorts. In a CIF analysis of all patients, there was no significant difference in the cumulative incidence of waitlist death between RCM/HCM and non-RCM/ HCM patients (sub-hazard ratio 
Predictors of Waitlist Death or Delisting for RCM/HCM: The UNOS RCM/HCM Risk Model
To create a validated risk model for patients with RCM/ HCM without MCSD, derivation and validation cohorts were created, with no significant differences found between groups (Table II in the Data Supplement). In the multivariate proportional hazards model of waitlist death or delisting for patients with RCM/HCM, subjective frailty, estimated glomerular filtration rate <60 mL/ min per 1.73 m 2 , PCWP >20 mm Hg, and inotrope use at listing were significant predictors of worse outcome (Table 3 ). An UNOS RCM/HCM risk model for waitlist death or delisting was created using these predictors. Frailty (HR, 3.78; P<0.01) and inotrope use at listing (HR, 3.74; P<0.01) had the highest HRs. However, the variability among the 4 variables was minimal, and each was assigned 1 point in the final risk model (for a maximum score of 4). The UNOS RCM/HCM Risk Model was calculated for all patients with RCM/HCM in the UNOS registry from 2006 to 2016. Eighty-eight percent of patients with RCM/HCM (1155 UNOS candidates) had data for all 4 predictors. Frailty data were missing for only 69 patients, and these patients were assumed to have no frailty. The distribution of the score within the UNOS population was relatively normal (Figure 2 ). ROC curve analysis demonstrated area under the curve of 0.79 for the derivation cohort an area under the curve of 0.75 for the validation cohort (P=0.49; Figure 3A ).
Additional ROC curves were derived separately for patients with RCM and patients with HCM revealed area under the curve of 0.80 and 0.71, respectively (P=0.13; Figure 3B ). Kaplan-Meier curves for waitlist death or delisting for worsening clinical status are displayed in Figure 4 . In the current allocation system, at 1 year, 91.4% of patients with a score of 0 to 1 were healthy enough to remain on the waitlist compared with only 38.6% of those with a score of 3 to 4.
DISCUSSION
Patients with end-stage RCM/HCM have unique physiology and inherent limitations on the use of MCSD. 16 Although the rise of VAD technology has transformed management for patients with DCM awaiting a heart transplant, the same impact has not been observed in the RCM/HCM patient population. This challenge presents at a particularly unique time with the expected rollout of the new heart allocation policy in the United States that emphasizes patients with MCSD. 13, 17 This study sought to evaluate MCSD utilization patterns and waitlist outcomes in patients with RCM/HCM and to create a clinical risk model that identifies high-risk patients who may require prioritization on the transplant waitlist. There were 4 important findings. First, patients with RCM/HCM are significantly less likely to be status 1A or status 1B at the time of listing, and their probability of receiving any MCSD is significantly lower, even within status 1A. Second, patients with RCM/ HCM wait fewer days on the waitlist. Third, there is no difference in the cumulative incidence of waitlist death between RCM/HCM and non-RCM/HCM patients, but patients with RCM/HCM are more likely to receive heart Competing risks of waitlist death, heart transplantation, and waitlist removal for other reasons were modeled. The incidence of waitlist death did not differ in restrictive cardiomyopathy (RCM)/hypertrophic cardiomyopathy (HCM) vs non-RCM/HCM patients (A). The incidence of transplant was significantly higher for patients with RCM/HCM compared with non-RCM/HCM patients (B). transplantation. Fourth, the UNOS RCM/HCM risk model created here may help identify patients with RCM/ HCM without MCSD who are at greatest risk for waitlist death or delisting because of clinical deterioration.
The structural and physiological impediments to MCSD in patients with RCM/HCM include smaller left ventricular (LV) size, increased myocardial stiffness, and the risk for obstruction of flow. 16, 18 Even among end-stage RCM/HCM with a relatively dilated LV cavity, LV end-diastolic diameter predicts LVAD outcomes; smaller LV end-diastolic dimension predicts substantially worse mortality. 10, [19] [20] [21] [22] Other complications of VAD use in patients with RCM/HCM include higher rates of right heart failure and inotrope dependence compared with patients with DCM. Notably, studies demonstrate that patients with restrictive physiology and VAD have similar 1-year survival and post-transplant outcomes to patients with DCM. 10, [19] [20] [21] 23 In 1 case report, a patient with an LV end-diastolic dimension of 9.1 cm received an LVAD and demonstrated early postoperative decompression of the LV with reversion to an HCM morphology and subsequent VAD dysfunction. 11 Although clearly an unusual situation, such remodeling in HCM has been previously reported with cardiac resynchronization therapy. 24 As such, the use of MCSD is understandably limited for these patients. Current patterns of utilization from our analysis demonstrate that patients with RCM/HCM are over 27% less likely to receive any MCSD than their non-RCM/HCM counterparts.
The current US organ allocation system succeeds in waitlist death parity between RCM/HCM and non-RCM/ HCM patients. No significant difference in the cumulative incidence of waitlist death was found between the 2 groups. In fact, patients with RCM/HCM were marginally more likely to receive a transplant and had fewer days on the waitlist. Among the sickest patients (status 1A), these differences were no longer evident, and there was parity in transplant incidence and waitlist time between the 2 cohorts. This suggests that the current system, despite its many challenges and need for status exceptions, serves the RCM/HCM population well. The present analysis emphasizes the importance of a high status listing for a patient to receive a heart transplant. A prior study of waitlist death in patients with RCM/ 
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HCM in the UNOS registry had concluded that patients with RCM were more likely to die. However, that study did not account for a multiple competing risks model. 25 Slated for implementation in late 2017/mid-2018, the new heart allocation system is focused on decreasing waitlist mortality and improving transplant opportunity for the sickest patients requiring heart transplantation in the United States. [12] [13] [14] 17, 26, 27 The new allocation system is timely in that it accounts for changes in waitlist mortality, 28 an increasing cohort of aging patients with end-stage heart failure eligible for transplant, and the growing utilization of MCSD. Under the new allocation system, MCSD patients are prioritized in statuses 1/2/3, and patients with RCM/HCM are eligible for status 4 ( Table 1 ). In public comment of the new policy, specialists and patient advocacy groups have raised some concerns about this discrepancy. Indeed, this issue has been recognized by the Thoracic Organ Transplantation Committee of the Organ Procurement and Transplantation Network/UNOS. This study bears out that concern with the data. Assuming no dramatic changes in MCSD utilization patterns, patients with RCM/HCM, therefore, may be potentially disadvantaged under the new allocation system. This will be theoretically applicable to any patients who are not ideal candidates for MCSD utilization, such as those with congenital heart disease. As such, a mechanism for identifying patients with RCM/HCM at high risk for clinical deterioration to expedite transplant may serve as a potential solution to address concerns of equity.
Our analysis identified 4 important predictors of waitlist death or delisting for the RCM/HCM cohort without MCSD: frailty, estimated glomerular filtration rate <60 mL/min per 1.73 m 2 , mean PCWP >20 mm Hg, and inotrope use at listing. In the UNOS RCM/HCM risk model proposed here, these predictors were weighted to create a score that can identify patients at high risk for waitlist death or delisting for worsening clinical status. The model was validated in a random cohort within the UNOS registry, separate from the derivation cohort. A high score accurately predicts negative outcomes for patients with RCM/HCM without MCSD, both as a combined cohort and separated out by diagnosis.
The 4 predictors included in the risk model have substantial evidence supporting their clinical importance. First, frailty is a more common comorbidity in heart failure with preserved ejection fraction than in heart failure with reduced ejection fraction, 29, 30 and patients with RCM/HCM-whose disease course typically begins with preserved ejection fraction-with systemic comorbidities are plausibly at high risk for frailty. 31 There has been no accepted standardized frailty measure in the advanced heart failure literature. [32] [33] [34] [35] Regardless of criteria, frail patients are more likely to experience decreased quality of life and increased mortality after VAD or heart transplant.
33,36-38 Second, renal dysfunc- tion is well-known to adversely affect outcomes in heart failure [39] [40] [41] [42] and has been shown to increase mortality risk in heart failure patients with restrictive filling specifically. 43, 44 Third, elevated PCWP is demonstrably elevated in patients with HCM undergoing transplantation (even when the ventricle is nondilated) 45 and in RCM. 46, 47 Fourth, inotrope use in end-stage heart failure can lead to increased mortality 25 and especially with respect to sudden death in patients with RCM 48 and increased LV outflow obstruction and cardiovascular collapse in patients with HCM. 49 The limitations of MCSD therapy in RCM/HCM highlight the importance of heart transplantation in this population. Under the proposed allocation policy, patients with RCM/HCM without MCSD face a relative disadvantage if categorized as status 4. The UNOS RCM/HCM risk model can be used to identify patients with the highest likelihood of a poor waitlist outcome. Status exceptions could then be granted to these at-risk patients with RCM/HCM to expedite heart transplantation-their only remaining treatment option. In this way, status exceptions can be equitably decided to protect waitlist outcomes for patients with RCM/HCM physiology.
Limitations
This study was a retrospective analysis with a relatively small number of patients with HCM/RCM. Longerterm outcome analyses are limited by the fact that the study analyzes data in the current era of MCSD and transplant. In addition, detailed information on MCSDs (pump speed, flow, power, pulsatility index) as well as echocardiographic data (LV size, LV thickness, and LV ejection fraction) were unavailable in the UNOS registry. Furthermore, data for the predictors identified were from the time of listing; trends over time were not available and would be helpful in assessing how patients' risk profiles may change as they wait for a heart transplantation. Outcome predictions under the new allocation policy are limited-the realities of a new policy cannot be directly modeled by behavior patterns under the current rules.
50
Conclusions
Patients with RCM/HCM are unique in their pathophysiology and comorbidities. This places them at a relative disadvantage when it comes to the utilization of MCSD therapy, highlighting the dependence on heart transplantation for patients with RCM/HCM. The UNOS RCM/HCM risk model that is derived from and successfully validated in UNOS Registry may allow for the identification of patients who are at high risk for waitlist mortality or delisting for worsening status and serve as a basis for review boards deciding on status exceptions in the new heart allocation system.
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